fluvoxamine and Brugada-Syndrome

fluvoxamine has been researched along with Brugada-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for fluvoxamine and Brugada-Syndrome

Article	Year
Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2010, Volume: 12, Issue:2 A patient with an SCN5A p.W822X nonsense mutation, localized in the transmembrane region DII-S4 of the Na(v)1.5 sodium channel and leading to a non-expression of the mutant allele, was prescribed the selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Floxyfral), 100 mg per day. His normal baseline ECG changed to a characteristic Brugada-Type-1-ECG pattern. To investigate whether fluvoxamine may reduce the cardiac sodium current, the effect of this drug was studied on the wild-type voltage-gated cardiac sodium channel Na(v)1.5 stably expressed in HEK293 cells. Patch-clamp recording showed a 50% inhibition of the current at a concentration of 57.3 microM. In our patient, no arrhythmia occurred but the proarrhythmic potential of SSRI in patients with SCN5A mutations cannot be excluded. Therefore, we advise 12-lead ECG control after administering SSRI in these patients. Topics: Adolescent; Brugada Syndrome; Depression; Electrocardiography; Fluvoxamine; Humans; Male; Muscle Proteins; Mutation; NAV1.5 Voltage-Gated Sodium Channel; Selective Serotonin Reuptake Inhibitors; Sodium Channels	2010

Article

Year

Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2010, Volume: 12, Issue:2

A patient with an SCN5A p.W822X nonsense mutation, localized in the transmembrane region DII-S4 of the Na(v)1.5 sodium channel and leading to a non-expression of the mutant allele, was prescribed the selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Floxyfral), 100 mg per day. His normal baseline ECG changed to a characteristic Brugada-Type-1-ECG pattern. To investigate whether fluvoxamine may reduce the cardiac sodium current, the effect of this drug was studied on the wild-type voltage-gated cardiac sodium channel Na(v)1.5 stably expressed in HEK293 cells. Patch-clamp recording showed a 50% inhibition of the current at a concentration of 57.3 microM. In our patient, no arrhythmia occurred but the proarrhythmic potential of SSRI in patients with SCN5A mutations cannot be excluded. Therefore, we advise 12-lead ECG control after administering SSRI in these patients.

Topics: Adolescent; Brugada Syndrome; Depression; Electrocardiography; Fluvoxamine; Humans; Male; Muscle Proteins; Mutation; NAV1.5 Voltage-Gated Sodium Channel; Selective Serotonin Reuptake Inhibitors; Sodium Channels

2010